Biomarker Lens

Biomarkers · Chemical

Tapentadol, Urine

Understand what Tapentadol, Urine signals

Primary unit
ng/mL
LOINC codes
106132-4, 10975-1, 11052-8, 11075-9, 12382-8, 12602-9, 15372-6, 16114-1, 16249-5, 17395-5, 17719-6, 18322-8, 18338-4, 18355-8, 19328-4, 19346-6, 19570-1, 19611-3, 2161-8, 2756-5, 28073-5, 2965-2, 33339-3, 33507-5, 3394-4, 3415-7, 3508-9, 3637-6, 3681-4, 3725-9, 3755-6, 3774-7, 3780-4, 3831-5, 3875-2, 3887-7, 3937-0, 49753-7, 50542-0, 54247-2, 58714-7, 59589-2, 59680-9, 60677-2, 61422-2, 61425-5, 64125-8, 65807-0, 65808-8, 72768-5, 82524-0, 96059-1, 9835-0, 10976-9, 10998-3, 11235-9, 11247-4, 12308-3, 3414-0, 3507-1, 3539-4, 3773-9, 3830-7, 41858-2, 43199-9, 43219-5, 73566-2, 86453-8, 95135-0, 9834-3, 16196-8, 16197-6, 16199-2, 16208-1, 17718-8, 18325-1, 18473-9, 19295-5, 19321-9, 19322-7, 19483-7, 19550-3, 19643-6, 19710-3, 40839-3, 43200-5, 58362-5, 58401-1, 58428-4, 59673-4, 61421-4, 61424-8, 72485-6, 73995-3, 92646-9, 92649-3, 69739-1
Commercial laboratory assays
9

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Tapentadol, Urine

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Buprenorphine MAT1, Urine, Medication Assisted Treatment (MAT)

Laboratory
Labcorp
Test code
701957
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect and confirm the presence of prescribed and illicit drugs for monitoring Suboxone™/buprenorphine medication assisted treatment (MAT). Please note this testing is designed specifically for monitoring patients who are on Suboxone™/buprenorphine only. This testing should not be used for monitoring chronic pain patients (medical drug monitoring) or methadone medication assisted treatment.

Labcorp test directory, test code 701957

Buprenorphine MAT2, Urine, Medication Assisted Treatment (MAT)

Laboratory
Labcorp
Test code
703040
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect and confirm presence of prescribed and illicit drugs for monitoring Suboxone™/buprenorphine medication assisted treatment (MAT). Please note this testing is designed specifically for monitoring patients who are on Suboxone™/buprenorphine only. This testing should not be used for monitoring chronic pain patients (medical drug monitoring) or methadone medication assisted treatment.

Labcorp test directory, test code 703040

Buprenorphine Medication Assisted Treatment Monitoring 2, Urine

Laboratory
Labcorp
Test code
701985
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect and confirm presence of prescribed and illicit drugs for monitoring Suboxone™/buprenorphine medication assisted treatment (MAT). Please note this testing is designed specifically for monitoring patients who are on Suboxone™/buprenorphine only. This testing should not be used for monitoring chronic pain patients (medical drug monitoring) or methadone medication assisted treatment.

Labcorp test directory, test code 701985

Drug Monitoring Assess Panel, Extended, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39992
Specimen
Urine
Fasting
Not stated
LOINC
106132-4, 10975-1, 11052-8, 11075-9, 12382-8, 12602-9, 15372-6, 16114-1, 16249-5, 17395-5, 17719-6, 18322-8, 18338-4, 18355-8, 19328-4, 19346-6, 19570-1, 19611-3, 2161-8, 2756-5, 28073-5, 2965-2, 33339-3, 33507-5, 3394-4, 3415-7, 3508-9, 3637-6, 3681-4, 3725-9, 3755-6, 3774-7, 3780-4, 3831-5, 3875-2, 3887-7, 3937-0, 49753-7, 50542-0, 54247-2, 58714-7, 59589-2, 59680-9, 60677-2, 61422-2, 61425-5, 64125-8, 65807-0, 65808-8, 72768-5, 82524-0, 96059-1, 9835-0

Laboratory assay overview

A single direct to definitive panel with the ability to identify multiple specific drugs and metabolites across drug classes facilitates enhanced patient care. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39992

Drug Monitoring, Opioids Panel, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39012
Specimen
Urine
Fasting
Not stated
LOINC
10976-9, 10998-3, 11235-9, 11247-4, 12308-3, 3414-0, 3507-1, 3539-4, 3773-9, 3830-7, 41858-2, 43199-9, 43219-5, 54247-2, 65807-0, 65808-8, 73566-2, 86453-8, 95135-0, 96059-1, 9834-3

Laboratory assay overview

Monitoring of parent compounds and their metabolites in urine. The results of this test are used in specific treatment programs to determine compliance with prescribed dosing schedules.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Buprenorphine<2 ng/mL
Norbuprenorphine<2 ng/mL
Naloxone<2 ng/mL
Fentanyl<0.5 ng/mL
Norfentanyl<0.5 ng/mL
Heroin Metabolite<10 ng/mL
Methadone<100 ng/mL
EDDP<100 ng/mL
Dextromethorphan<20 ng/mL
Dextrorphan<20 ng/mL
Mitragynine<2 ng/mL
Codeine<50 ng/mL
Hydrocodone<50 ng/mL
Hydromorphone<50 ng/mL
Norhydrocodone<50 ng/mL
Morphine<50 ng/mL
Oxycodone<50 ng/mL
Oxymorphone<50 ng/mL
Noroxycodone<50 ng/mL
Tapentadol<50 ng/mL
Nortapentadol<50 ng/mL
Tramadol<100 ng/mL
O-desmethyltramadol<100 ng/mL
View complete laboratory reference notes

Buprenorphine <2 ng/mL Norbuprenorphine <2 ng/mL Naloxone <2 ng/mL Fentanyl <0.5 ng/mL Norfentanyl <0.5 ng/mL Heroin Metabolite <10 ng/mL Methadone <100 ng/mL EDDP <100 ng/mL Dextromethorphan <20 ng/mL Dextrorphan <20 ng/mL Mitragynine <2 ng/mL Codeine <50 ng/mL Hydrocodone <50 ng/mL Hydromorphone <50 ng/mL Norhydrocodone <50 ng/mL Morphine <50 ng/mL Oxycodone <50 ng/mL Oxymorphone <50 ng/mL Noroxycodone <50 ng/mL Tapentadol <50 ng/mL Nortapentadol <50 ng/mL Tramadol <100 ng/mL O-desmethyltramadol <100 ng/mL

Quest Diagnostics test directory, test code 39012

Drug Monitoring, Opioids Panel, with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39013
Specimen
Urine
Fasting
Not stated
LOINC
16196-8, 16197-6, 16199-2, 16208-1, 17718-8, 18325-1, 18473-9, 19295-5, 19321-9, 19322-7, 19483-7, 19550-3, 19643-6, 19710-3, 3414-0, 40839-3, 43200-5, 54247-2, 58362-5, 58401-1, 58428-4, 59673-4, 61421-4, 61424-8, 72485-6, 73566-2, 73995-3, 92646-9, 92649-3

Laboratory assay overview

Monitoring of parent compounds and their metabolites in urine. The results of this test are used in specific treatment programs to determine compliance with prescribed dosing schedules.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Buprenorphinenot stated
Buprenorphine<2 ng/mL
Norbuprenorphine<2 ng/mL
Naloxone<2 ng/mL
Fentanylnot stated
Fentanyl<0.5 ng/mL
Norfentanyl<0.5 ng/mL
Heroin Metabolitenot stated
Heroin Metabolite<10 ng/mL
Methadonenot stated
Methadone<100 ng/mL
EDDP<100 ng/mL
Methorphannot stated
Dextromethorphan<20 ng/mL
Dextrorphan<20 ng/mL
Mitragyninenot stated
Mitragynine<2 ng/mL
Opiatesnot stated
Codeine<50 ng/mL
Hydrocodone<50 ng/mL
Hydromorphone<50 ng/mL
Norhydrocodone<50 ng/mL
Morphine<50 ng/mL
Oxycodone<50 ng/mL
Oxymorphone<50 ng/mL
Noroxycodone<50 ng/mL
Tapentadolnot stated
Tapentadol<50 ng/mL
Nortapentadol<50 ng/mL
Tramadolnot stated
Tramadol<100 ng/mL
O desmethyltramadol<100 ng/mL
View complete laboratory reference notes

Buprenorphine Buprenorphine <2 ng/mL Norbuprenorphine <2 ng/mL Naloxone <2 ng/mL Fentanyl Fentanyl <0.5 ng/mL Norfentanyl <0.5 ng/mL Heroin Metabolite Heroin Metabolite <10 ng/mL Methadone Methadone <100 ng/mL EDDP <100 ng/mL Methorphan Dextromethorphan <20 ng/mL Dextrorphan <20 ng/mL Mitragynine Mitragynine <2 ng/mL Opiates Codeine <50 ng/mL Hydrocodone <50 ng/mL Hydromorphone <50 ng/mL Norhydrocodone <50 ng/mL Morphine <50 ng/mL Oxycodone <50 ng/mL Oxymorphone <50 ng/mL Noroxycodone <50 ng/mL Tapentadol Tapentadol <50 ng/mL Nortapentadol <50 ng/mL Tramadol Tramadol <100 ng/mL O desmethyltramadol <100 ng/mL

Quest Diagnostics test directory, test code 39013

Drug Screen Only 18, Urine, Medication Assisted Treatment (MAT)

Laboratory
Labcorp
Test code
705540
Specimen
Urine
Fasting
Not stated
LOINC
69739-1
Turnaround
1 - 2 days

Laboratory assay overview

This test is used to detect the presence of prescribed and illicit drugs for monitoring treatment of substance use disorder, including medication assisted treatment (MAT).

Labcorp test directory, test code 705540

Tapentadol, Screen and Confirmation, Urine

Laboratory
Labcorp
Test code
764170
Specimen
Urine
Fasting
Not stated
LOINC
72485-6
Turnaround
3 - 5 days

Laboratory assay overview

Detect and confirm the presence of tapentadol

Labcorp test directory, test code 764170

Tapentadol, Screen Only, Urine

Laboratory
Labcorp
Test code
701900
Specimen
Urine
Fasting
Not stated
Turnaround
2 - 4 days

Laboratory assay overview

Drug analysis/clinical drug monitoring

Labcorp test directory, test code 701900

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.